Analytical Data
-
基因名
BHRF1
- Application
-
别名
BHRF1；GT197；Beclin-1
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P03182
-
表达区间
1-142aa
-
氨基酸序列
MAYSTREILLALCIRDSRVHGNGTLHPVLELAARETPLRLSPEDTVVLRYHVLLEEIIERNSETFTETWNRFITHTEHVDLDFNSVFLEIFHRGDPSLGRALAWMAWCMHACRTLCCNQSTPYYVVDLSVRGMLEASEGLDG
-
分子量
19.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BHRF1, a protein encoded by the Epstein-Barr virus (EBV), plays a critical role in the virus's ability to evade host immune responses. This viral protein is part of the MHC class I downregulation mechanism, allowing infected cells to escape detection by cytotoxic T lymphocytes. Research into BHRF1 has gained momentum in recent years due to its implications in EBV-associated malignancies, including Burkitt's lymphoma and nasopharyngeal carcinoma. Understanding the structure and function of BHRF1 can provide insights into how EBV persists in the host and contributes to oncogenesis. Moreover, BHRF1's ability to inhibit apoptosis suggests potential therapeutic targets for enhancing the immune response against EBV-infected cells. The production of recombinant BHRF1 protein in a laboratory setting enables researchers to investigate its specific interactions with host cellular machinery and to explore its potential as a vaccination or therapeutic candidate. Overall, the study of BHRF1 not only advances our understanding of viral pathogenesis but also offers avenues for innovative clinical applications in viral infections and cancer therapy.
